In vitro susceptibility of neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes

Ahuva Cern; Kristie L. Connolly; Ann E. Jerse; Yechezkel Barenholz

doi:10.1128/AAC.02377-17

In vitro susceptibility of neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes

Ahuva Cern^*, Kristie L. Connolly, Ann E. Jerse, Yechezkel Barenholz

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Neisseria gonorrhoeae is an urgent antibiotic-resistant threat. This study determined the MICs of mupirocin to be 0.0039 to 0.0625 μg/ml for 94 N. gonorrhoeae strains. Cross-resistance with other antibiotics was not detected. Mupirocin, which is currently limited to topical administration, demonstrated activity by injection when delivered in nanoliposomes. The nanoliposomal formulation of mupirocin is a potential treatment for drug-resistant N. gonorrhoeae.

Original language	English
Article number	e02377-17
Journal	Antimicrobial Agents and Chemotherapy
Volume	62
Issue number	4
DOIs	https://doi.org/10.1128/AAC.02377-17
State	Published - Apr 2018
Externally published	Yes

Keywords

Antibiotic resistance
Antimicrobial activity
Antimicrobial resistance
Cross-resistance
Liposomes
Nano-mupirocin

Access to Document

10.1128/AAC.02377-17

Cite this

@article{b40fd492643a4691a739a092603d082d,

title = "In vitro susceptibility of neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes",

abstract = "Neisseria gonorrhoeae is an urgent antibiotic-resistant threat. This study determined the MICs of mupirocin to be 0.0039 to 0.0625 μg/ml for 94 N. gonorrhoeae strains. Cross-resistance with other antibiotics was not detected. Mupirocin, which is currently limited to topical administration, demonstrated activity by injection when delivered in nanoliposomes. The nanoliposomal formulation of mupirocin is a potential treatment for drug-resistant N. gonorrhoeae.",

keywords = "Antibiotic resistance, Antimicrobial activity, Antimicrobial resistance, Cross-resistance, Liposomes, Nano-mupirocin",

author = "Ahuva Cern and Connolly, {Kristie L.} and Jerse, {Ann E.} and Yechezkel Barenholz",

year = "2018",

month = apr,

doi = "10.1128/AAC.02377-17",

language = "English",

volume = "62",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology 1752 N St., NW, Washington, DC",

number = "4",

}

TY - JOUR

T1 - In vitro susceptibility of neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes

AU - Cern, Ahuva

AU - Connolly, Kristie L.

AU - Jerse, Ann E.

AU - Barenholz, Yechezkel

PY - 2018/4

Y1 - 2018/4

N2 - Neisseria gonorrhoeae is an urgent antibiotic-resistant threat. This study determined the MICs of mupirocin to be 0.0039 to 0.0625 μg/ml for 94 N. gonorrhoeae strains. Cross-resistance with other antibiotics was not detected. Mupirocin, which is currently limited to topical administration, demonstrated activity by injection when delivered in nanoliposomes. The nanoliposomal formulation of mupirocin is a potential treatment for drug-resistant N. gonorrhoeae.

AB - Neisseria gonorrhoeae is an urgent antibiotic-resistant threat. This study determined the MICs of mupirocin to be 0.0039 to 0.0625 μg/ml for 94 N. gonorrhoeae strains. Cross-resistance with other antibiotics was not detected. Mupirocin, which is currently limited to topical administration, demonstrated activity by injection when delivered in nanoliposomes. The nanoliposomal formulation of mupirocin is a potential treatment for drug-resistant N. gonorrhoeae.

KW - Antibiotic resistance

KW - Antimicrobial activity

KW - Antimicrobial resistance

KW - Cross-resistance

KW - Liposomes

KW - Nano-mupirocin

UR - http://www.scopus.com/inward/record.url?scp=85043395834&partnerID=8YFLogxK

U2 - 10.1128/AAC.02377-17

DO - 10.1128/AAC.02377-17

M3 - Article

C2 - 29339382

AN - SCOPUS:85043395834

SN - 0066-4804

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 4

M1 - e02377-17

ER -